Neurocrine sheds 200 Indiplon reps

Share this article:
Neurocrine Biosciences has laid off its entire 200-person sales force, the San Diego firm said. The decision follows Pfizer's ending of its marketing partnership with Neurocrine after the latter lost approval for insomnia drug Indiplon, and Pfizer lost US patent protection for Zoloft.

Neurocrine was then unable to acquire a product to keep the reps busy as it continues to seek FDA approval for Indiplon.

Neurocrine plans to meet with the FDA to finalize plans for the resubmission of each Indiplon NDA and to commercialize Indiplon quickly upon approval.
Neurocrine also said it is reviewing other possible future partnerships.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...